Atherosclerotic Cardiovascular Disease

New research links increased dietary selenium intake to reduced cardiovascular disease risk, highlighting its potential benefits for heart health.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

A secondary analysis of the data collected by the DASH-Sodium trial indicates that dieting and sodium intake limits are additive in their effects on ASCVD risk.

Orchestra BioMed’s Breakthrough Device designation could apply to nearly 8 million patients with uncontrolled hypertension and increased cardiovascular risk

Anita Radhakrishnan, MD, leads a community screening effort to detect early heart disease in underserved populations in Pittsburgh.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Label updates simplify twice-yearly echo monitoring for eligible patients in the maintenance phase and expand eligibility with reduced contraindications.

Radhakrishnan describes a unique initiative in Pittsburgh promoting health equity and closing the gap in cardiovascular health disparities.

This episode spotlights a pair of studies examining use of semaglutide from the American College of Cardiology's 2025 Scientific Sessions.

Individuals treated with ezetimibe shortly after myocardial infarction experience an improved prognosis versus those who receive delayed treatment or none at all.

Bristol Myers Squibb says mavacamten missed dual primary endpoints in Phase 3 ODYSSEY-HCM trial for symptomatic non-obstructive HCM.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

A recap of 10 clinical trials in cardiovascular care to know from the American College of Cardiology 2025 Scientific Sessions.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

At ACC.25, Boer highlights treatment gaps in the US for lipid control in a high-risk ASCVD population.

Patients with PAH saw a 76% reduction in the composite of morbidity and mortality outcomes with sotatercept treatment.

At ACC.25, Robert S. Rosenson, MD, discusses the efficacy and safety of solbinsiran, an ANGPTL3 inhibitor, in a population with mixed dyslipidemia.

Hosts break down the STRIDE and SOUL trial results and reflect on how they might inform treatment strategies in the respective patient populations.

Four-year results from SOUL at ACC.25 were the first to test the cardiovascular benefits of an oral GLP-1 RA in high-risk type 2 diabetes.